Published in Biotech Law Weekly, November 11th, 2005
Trexima is the proposed brand name for the combination of sumatriptan succinate, formulated with RT Technology, and naproxen sodium, in a single tablet for the acute treatment of migraine. The NDA seeking marketing approval in the U.S. was submitted on August 8, 2005. Pending FDA approval, the product could be available to patients as early as second-half 2006.
"The Trexima NDA acceptance is an important milestone for POZEN," stated Dr. John Plachetka, POZEN's chairman,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.